Skip to content
Screener

Amphastar Pharmaceuticals AMPH Total Operating Expenses

Total Operating Expenses at other companies

Viatris logo
ViatrisVTRS
$1.45B+31.8%
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
$82.83M+83.4%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$60.19M+8.8%

Other financials

Income statement

See full
Revenue$183.9M+5.4%
Gross profit$93.5M+8.1%
Operating income$39.7M-5.8%
Net income$30.3M-2.2%
EPS (diluted)$0.67+4.7%

Balance sheet

See full
Cash & equivalents$223.6M+19.1%
Total debt$688.5M+5.0%
Total equity$445.5M
Total assets$1.7B+8.0%

Cash flow

See full
Operating cash flow$51.3M+44.2%
CapEx$8.6M-18.7%
Free cash flow$42.7M+70.7%

Valuation

See full
Market cap$863.95M-32.1%
Enterprise value$1.33B-23.6%
P/E11×+1.6×
P/S1.2×-0.6×

Profitability

See full
Gross margin47.7%-2.2pp
Operating margin15.7%-9.5pp
Net margin10.8%-7.9pp
FCF margin20.9%+5.4pp

Returns & leverage

See full
Return on equity14.7%
Debt / equity0.2×
Current ratio2.4×-0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:50 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001297184-26-000047
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Selling, distribution, and marketing13,33510,23525,26222,101
General and administrative18,24213,99136,27029,987
Research and development22,16420,08048,90140,176
Total operating expenses53,74144,306110,43392,264
Income from operations39,72942,18453,35979,477
Non-operating expenses:
Interest income2,2871,9214,6874,010
Interest expense(6,659)(6,281)(13,212)(12,567)

Item 1. Financial Statements (unaudited)

FAQ

What is Amphastar Pharmaceuticals's total operating expenses?
Amphastar Pharmaceuticals (AMPH) reported total operating expenses of $53.74M in Q2 2026.
How has Amphastar Pharmaceuticals's total operating expenses changed year-over-year?
Amphastar Pharmaceuticals's total operating expenses increased by 21.3% year-over-year, from $44.31M to $53.74M.
What is the long-term trend for Amphastar Pharmaceuticals's total operating expenses?
Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's total operating expenses has grown at a 13.5% compound annual growth rate (CAGR), from $129.85M to $215.65M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.

Ask your AI about Amphastar Pharmaceuticals's total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude